Kudrow D, Croop RS, Thiry A, Lipton RB, et al. A 52-week open-label extension study to evaluate the safety and efficacy of oral rimegepant for the preventive treatment of migraine. Headache 2025 Jun 30. doi: 10.1111/head.15002.
PMID: 40583813